ANGIOPOIETIN-2 GENE POLYMORPHISM IN SPORADIC PROSTATE CANCER

Basit Öğe Kaydı
dc.contributor.authorOnen, H. Ilke
dc.contributor.authorKonac, Ece
dc.contributor.authorEroglu, Muzaffer
dc.contributor.authorEkmekci, Abdullah
dc.date.accessioned2024-09-25T19:56:20Z
dc.date.available2024-09-25T19:56:20Z
dc.date.issued2007
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractPurpose: Angiogenesis is a critical requirement for local proliferation and metastasis of prostate cancer. Single nucleotide polymorphisms in angiogenesis-dependent genes affect the degree of cancer development and progression. Angiopoietin-2 (ANGPT-2) is one of the principal regulators of vascular growth and regression; however, its role in normal prostate and prostate tumors is largely unknown. DNA sequence variations in ANGPT-2 may alter the production outcomes or activities of the genes. In this study, we aimed to determine how the changes in the ANGPT-2 exon 4 G/A affect sporadic prostate cancer patients in the Turkish population. Materials and Methods: A case-control study on 52 sporadic prostate cancer patients and 52 healthy control subjects was conducted. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses were performed to identify different ANGPT-2 alleles. Results: The distribution of genotype and allele frequencies of the polymorphism did not yield a statistically significant difference between patients and controls (P>0.05). Furthermore, classification of patients by tumor, lymph nodes, metastasis (TNM), Gleason scores (GS), and serum prostatespecific antigen (PSA) levels showed no significant differences among the ANGPT-2 exon 4 G/A genotypes (P>0.05). Conclusion: This is the first report on the ANGPT-2 exon 4 G/A polymorphism in patients with sporadic prostate cancer demonstrating that the investigated polymorphism is not associated with prostate cancer in the Turkish population.en_US
dc.description.sponsorshipGazi University Research Fund [11/200305]en_US
dc.description.sponsorshipThis study has been particilly supported by the Gazi University Research Fund, with the project code number 11/200305.en_US
dc.identifier.endpage126en_US
dc.identifier.issn2147-2092
dc.identifier.issue3en_US
dc.identifier.startpage121en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13231
dc.identifier.volume18en_US
dc.identifier.wosWOS:000217426000006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGazi Univ, Fac Meden_US
dc.relation.ispartofGazi Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectAngiopoietin-2en_US
dc.subjectpolymorphismen_US
dc.subjectprostate canceren_US
dc.subjectrisk factoren_US
dc.titleANGIOPOIETIN-2 GENE POLYMORPHISM IN SPORADIC PROSTATE CANCERen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu